MedTrace Logo

Entecavir for Chronic Hepatitis B

NCT01323452 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 418

Last updated 2011-03-25

No results posted yet for this study

Summary

The primary aim of this study is to asses the efficacy (both virological and clinical) and safety of ETV in both NA-naïve and NA-experienced chronic hepatitis B patients, and to explore baseline factors associated with virologic reponse (VR) to ETV.

Conditions

  • Entecavir for Chronic Hepatitis B Patients

Interventions

DRUG

Entecavir

once daily

Sponsors & Collaborators

  • Foundation for Liver Research

    lead OTHER

Principal Investigators

  • Harry LA Janssen, MD, PhD · Erasmus Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-01-31
Completion
2011-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01323452 on ClinicalTrials.gov